Recent studies have intriguingly demonstrated a reduction in the MEG3 expression levels in various tumors, where it functions as a tumor suppressor through p53-dependent and p53-independent pathways (58, 59) (Figure 1). The gene discussed is TP53; the disease is neoplasm.